Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection.

Autor: Shouse G; City of Hope National Medical Center, Duarte, CA, United States of America. Electronic address: gshouse@coh.org.
Jazyk: angličtina
Zdroj: Blood reviews [Blood Rev] 2024 Nov 26, pp. 101251. Date of Electronic Publication: 2024 Nov 26.
DOI: 10.1016/j.blre.2024.101251
Abstrakt: Bispecific antibody therapy has revolutionized the treatment of hematologic malignancies. There are currently 7 FDA approved products with 4 different targets covering 5 indications in 4 diseases. Products include blinatumomab targeting B-cell ALL in MRD detectable first remission and in relapsed and/or refractory disease, elranatamab and teclistamab targeting BCMA in relapsed/refractory multiple myeloma, talquetamab targeting GPCR5D in multiple myeloma, and mosunetuzumab, epcoritamab and glofitamab which all target CD20 in follicular lymphoma, both follicular and large B cell lymphoma, or large B cell lymphoma alone, respectively. Each product utilizes the strategy of T-cell redirection by binding CD3 on the effector cell to target immune cells toward a tumor associated antigen. There are overlapping toxicities related to activation of the immune system and inflammation. The role of these agents in earlier lines of therapy and in novel combinations are under heavy investigation and their full utility and benefit in the treatment of hematologic malignancies is yet to be fully realized.
Competing Interests: Declaration of competing interest GS has worked as a consultant and on a speaker bureau for Beigene USA, Inc., and Kite Pharmaceuticals.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: